A Phase 2 randomised trial in 145 adults found once-weekly ecnoglutide lowered HbA1c by up to 2.39% versus 0.55% with placebo over 20 weeks. PICO summary and expert commentary.
Browsing: Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
A SURMOUNT-2 subpopulation analysis of 41 Japanese adults with type 2 diabetes and obesity, in which once-weekly tirzepatide produced significant 72-week weight loss versus placebo, tempered by a very small sample. PICO summary and expert commentary.
A post hoc analysis of SUSTAIN China asked whether baseline traits modify the glycaemic effect of once-weekly semaglutide versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
A small double-blind RCT in 38 patients with type 2 diabetes and coronary disease found pre-operative liraglutide gave better intra-operative glucose control and described regional epicardial fat microRNA patterns. PICO summary and expert commentary.
A small randomized three-arm trial comparing empagliflozin, sitagliptin, and metformin on glycemic and cardio-metabolic parameters in type 2 diabetes, with significance shown mainly against the metformin arm. PICO summary and expert commentary.
In the SOGALDI-PEF crossover trial, adding spironolactone to dapagliflozin produced a modest 11% NT-proBNP reduction in HFmrEF/HFpEF, offset by eGFR decline and higher potassium. PICO summary and expert commentary.
An RCT finds adding semaglutide to metformin improves weight, testosterone, and natural pregnancy rates in women with PCOS. PICO summary and expert commentary.
A small 52-week single-centre randomised trial found once-weekly semaglutide shifted lipoprotein subfractions toward a less atherogenic profile versus sitagliptin in type 2 diabetes. PICO summary and expert commentary.
Clinical Context SGLT2 inhibitors like canagliflozin are cornerstone medications for type 2 diabetes, providing glycemic control alongside cardiovascular and renal…
A double-blind randomised trial of dapagliflozin versus placebo for myocardial fibrosis on cardiac MRI in 100 patients with type 2 diabetes and HFpEF. PICO summary and expert commentary.